# UNAUDITED INTERIM FINANCIAL REPORT FOR THE FIFTH QUARTER ENDED 31 DECEMBER 2023

### CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2023

		INDIVIDUA	L PERIOD	CUMMULAT	TIVE PERIOD
	Note	Current Period Quarter 31.12.2023 RM	Preceding Period Quarter <sup>(i)</sup> 31.12.2022 RM		Preceding Period Period-to-date <sup>(i)</sup> 31.12.2022 RM
Revenue		4,652,038	-	18,348,013	-
Cost of sales	_	(10,735,019)	-	(46,036,797)	-
Gross loss		(6,082,981)	-	(27,688,784)	-
Other income		411,870	-	6,442,572	-
Interest income		130,496	-	901,187	-
Net impairment loss on financial ass	sets	(72,653)	-	(670,676)	-
Selling and distribution expenses		(41,952)	-	(209,799)	-
Administration expenses		(3,127,198)	-	(18,099,390)	-
Other expenses		(1,227,826)	-	(1,248,844)	-
Finance costs		(350,108)	-	(1,559,626)	-
Share of loss of associate companie	s _	(63,593)	_	(485,104)	
Loss before taxation		(10,423,945)	-	(42,618,464)	-
Tax expense	_	(214,307)		(1,571,449)	
Loss after taxation		(10,638,252)	-	(44,189,913)	-
Other comprehensive (loss)/income	-	(8,071)	-	60,368	-
Total comprehensive expense for the financial period	-	(10,646,323)		(44,129,545)	
Loss after taxation attributable to	):-	(0.050.111)		(40,562,276)	
Owners of the Company		(9,050,111)	-	(40,562,276)	
Non-controlling interests	-	(1,588,141)	-	(3,627,637)	
	=	(10,638,252)	-	(44,189,913)	-
Total comprehensive expense attr	ibutable to:				
Owners of the Company		(9,058,182)	-	(40,501,908)	
Non-controlling interests	-	(1,588,141) (10,646,323)		(3,627,637) (44,129,545)	-
	-	(10,040,323)		(44,129,545)	
Loss per share attributable to equity holders of the Company (sen)					
- Basic	B10.1	(0.18)	-	(0.79)	-
- Diluted	B10.2	(0.18)	-	(0.79)	-

Notes:

(i) In view of the change of financial year end from 12 months ended 30 September 2023 to 18 months ending 31 March 2024, there are no comparative figures for the preceding period quarter and preceding period-to-date. The current reporting financial period is for a period of 15 months, made up from 1 October 2022 to 31 December 2023.

(ii) The condensed consolidated statements of profit or loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 30 September 2022 and the accompanying explanatory notes attached to the quarterly report.

### CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT 31 DECEMBER 2023

	As at 31.12.2023 (Unaudited) RM	As at 30.9.2022 (Audited) RM
ASSETS		
Non-current assets		
Property, plant and equipment	143,631,238	131,691,143
Investment properties	2,249,587	-
Investment in associate companies	59,913,987	20,000
Goodwill on consolidation	6,083,027	6,083,027
Other investments	10,521,358	9,520,033
Trade receivables	-	2,000,000
Fixed deposits with licensed banks	-	2,319,629
Total non-current assets	222,399,197	151,633,832
Comment of second		
Current assets Inventories	11 440 565	22.015.077
Trade receivables	11,449,565	23,915,967 166,229,641
	115,657,525	
Other receivables Amount due from a joint venture company	14,596,144	14,358,821 53,117
Amount due from an associate	275,030	269,473
Tax recoverable	4,391,919	1,049,600
Fixed deposits with licensed banks	206,178	247,818
Cash and bank balances	36,073,817	74,181,222
Total current assets	182,650,178	280,305,659
	182,030,178	280,303,039
TOTAL ASSETS	405,049,375	431,939,491
EQUITY AND LIABILITIES Equity		
Share capital	251,446,486	251,446,486
Irredeemable convertible preference shares	35,878	35,878
Fair value reserve	(863,432)	(863,432)
Foreign currency translation reserve	60,368	-
Retained earnings	100,702,489	137,707,582
Equity attributable to owners of the Company	351,381,789	388,326,514
Non-controlling interests	10,611,411	2,796,231
Total equity	361,993,200	391,122,745
Non-current liabilities		
Lease liabilities	12,749,920	558,951
Deferred tax liabilities	927,631	927,631
Bank borrowings	10,680,094	12,318,861
Total non-current liabilities	24,357,645	13,805,443
I VIALHOIT CHI I CHI HAUMIICS	24,337,043	15,005,445

### CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT 31 DECEMBER 2023 (CONT'D)

	As at 31.12.2023 (Unaudited) RM	As at 30.9.2022 (Audited) RM
Current liabilities		
Trade payables	3,440,048	8,911,416
Other payables	12,526,598	11,097,676
Lease liabilities	1,321,676	374,205
Bank borrowings	1,350,549	1,290,592
Tax payable	59,659	5,337,414
Total current liabilities	18,698,530	27,011,303
TOTAL LIABILITIES	43,056,175	40,816,746
TOTAL EQUITY AND LIABILITIES	405,049,375	431,939,491
Net assets per share attributable to owners of the Company (sen)	6.88	7.60

(The condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the financial year ended 30 September 2022 and the accompanying explanatory notes attached to the quarterly report.)

#### CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2023

	<> Attributable To Owners of the Company>							
		Non-Distributable			Distributable			
	Share capital RM	Irredeemable convertible preference shares RM	Fair value reserve RM	Foreign currency translation reserve RM	Retained earnings RM	Total RM	Non- controlling interests RM	Total equity RM
At 1 October 2022	251,446,486	35,878	(863,432)	-	137,707,582	388,326,514	2,796,231	391,122,745
Net loss for the financial period Other comprehensive income for the financial period: - Share of foreign currency translation difference of	-	-	-	-	(40,562,276)	(40,562,276)	(3,627,637)	(44,189,913)
an associate company		_	-	60,368	-	60,368	-	60,368
Total comprehensive expense for the financial period	-	-	-	60,368	(40,562,276)	(40,501,908)	(3,627,637)	(44,129,545)
<b>Transactions with owners:</b> Changes in subsidiaries' ownership interests that do not result in a loss of control	-	-	-	-	3,557,183	3,557,183	11,442,817	- 15,000,000
Balance at 31 December 2023	251,446,486	35,878	(863,432)	60,368	100,702,489	351,381,789	10,611,411	361,993,200

Notes:

(i) In view of the change of financial year end from 12 months ended 30 September 2023 to 18 months ending 31 March 2024, there is no comparative figure for the preceding period-to-date. The current reporting financial period is for a period of 15 months, made up from 1 October 2022 to 31 December 2023.

(ii) The condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 30 September 2022 and the accompanying explanatory notes attached to the quarterly report.

### CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2023

	Current Period Period-to-date 31.12.2023 RM	Preceding Period Period-to-date <sup>(i)</sup> 31.12.2022 RM
CASH FLOW FROM OPERATING ACTIVITIES		
Loss before taxation	(42,618,464)	-
Adjustments for:		
Non-cash items	15,890,438	-
Non-operating items	(1,063,621)	
Operating loss before working capital changes	(27,791,647)	-
Net changes in inventories	8,956,801	-
Net changes in receivables	50,563,384	-
Net changes in payables	(3,166,569)	-
Net changes in contract liabilities	4,039,337	
Cash from operations	32,601,306	-
Interest paid	(1,559,626)	-
Income tax refund	780,204	-
Income tax paid	(10,971,727)	
Net cash from operating activities	20,850,157	
CASH FLOW FOR INVESTING ACTIVITIES		
Net cash inflow from the acquisition		
of subsidiary companies	590,006	-
Repayment from a joint venture company	317	-
Investment in an associate company	(60,319,731)	-
Advances to an associate company	(5,557)	-
Purchase of other investments	(1,001,325)	-
Interest received	901,187	-
Net cash outflow from the disposal of a subsidiary company	(3,108,690)	-
Proceeds from the disposal of plant and equipment	189,408	-
Net proceeds from the disposal of an investment	5,145,000	-
Purchase of property, plant and equipment	(14,323,318)	-
Purchase of investment properties	(2,276,800)	-
Subscription by non-controlling interests in the shares		
of subsidiary companies	15,000,000	
Net cash for investing activities	(59,209,503)	
CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of bank borrowings	(1,578,810)	-
Release of fixed deposits pledged	2,319,629	-
Repayment of lease liabilities	(532,755)	-
Net cash from financing activities	208,064	

### CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2023 (CONT'D)

	Current Period Period-to-date 31.12.2023 RM	Preceding Period Period-to-date <sup>(i)</sup> 31.12.2022 RM
Net changes in cash and cash equivalents	(38,151,282)	-
Effects on exchange rate differences	2,237	-
Cash and cash equivalents at the beginning of the financial period	74,384,040	
Cash and cash equivalents at the end of the financial period	36,234,995	
Analysis of cash and cash equivalents		
Fixed deposits	206,178	-
Cash and bank balances	36,073,817	
	36,279,995	-
Less: Fixed deposits pledged	(45,000)	-
	36,234,995	-

Notes:

(ii) The condensed consolidated statements of cash flows should be read in conjunction with the audited financial statements for the financial year ended 30 September 2022 and the accompanying explanatory notes attached to the quarterly report.

<sup>(</sup>i) In view of the change of financial year end from 12 months ended 30 September 2023 to 18 months ending 31 March 2024, there is no comparative figure for the preceding period-to-date. The current reporting financial period is for a period of 15 months, made up from 1 October 2022 to 31 December 2023.

### PART A: EXPLANATORY NOTES PURSUANT TO MFRS 134

### A1. Change in Financial Year End

As announced on 21 July 2023, the Group has changed its financial year end from 30 September to 31 March. Accordingly, the current financial period covers an eighteen (18)-month period from 1 October 2022 to 31 March 2024.

### A2. Basis of preparation

The interim financial statements are unaudited and have been prepared in accordance with the requirements of Malaysian Financial Reporting Standard ("MFRS") 134: Interim Financial Reporting and paragraph 9.22 of the Main Market Listing Requirements ("Listing Requirements") of Bursa Malaysia Securities Berhad ("Bursa Securities").

The interim financial statements should be read in conjunction with the audited financial statements of Hong Seng Consolidated Berhad ("Hong Seng" or the "Company") and its subsidiary companies ("Group") for the financial year ended 30 September 2022.

The accounting policies adopted by the Group in the interim financial statements are consistent with those adopted in the audited financial statements for the financial year ended 30 September 2022 except for the adoption of the new and revised MFRSs which are mandatory for financial periods beginning on or after 1 October 2022.

### A3. Qualification of financial statements

The auditors' report of the preceding financial statements for the financial year ended 30 September 2022 was not subject to any audit qualification.

### A4. Seasonal or cyclical factors

The business of the Group was not materially affected by any significant seasonal or cyclical factors during the current quarter under review.

### A5. Unusual items due to their nature, size or incidence

There were no unusual items affecting assets, liabilities, equity, net income or cash flow of the Group during the current quarter under review.

#### A6. Significant estimates and changes in estimates

There were no changes in the estimates of amounts reported in the prior financial period, which have a material effect in the current quarter under review.

### A7. Debts and equity securities

There were no issuance, cancellation, repurchase, resale and repayment of debt and equity securities for the current quarter under review.

### A8. Dividends paid

There was no dividend paid during the current quarter under review.

### A9. Segmental information

The Group's segmental report is presented based on its operating segments as follows:-

For the financial period ended 31 December 2023	Healthcare RM '000	Financial Services RM '000	Gloves RM '000	Others RM '000	Total RM '000	Adjustments and eliminations RM '000	Total RM '000
Sales to external customers Inter-segment sales	7,326 180	7,066	3,758	198	18,348 180	- (180)	18,348
Total sales	7,506	7,066	3,758	198	18,528	(180)	18,348
(Loss)/Profit before taxation	(9,700)	5,889	(41,866)	1,815	(43,862)	1,244	(42,618)
Segment assets	74,320	94,985	130,233	372,948	672,486	(267,437)	405,049
Segment liabilities	29,812	91,779	72,001	23,381	216,973	(173,917)	43,056
For the financial period ended 31 December 2022**	Healthcare	Financial Services	Gloves	Other	Total	Adjustments and eliminations	Total
ciacu of December 2022	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
Sales to external customer Inter-segment sales Total sales	RM'000 - - -	RM'000 - - -	010100				
Sales to external customer Inter-segment sales		-	RM'000	RM'000	RM'000 -		
Sales to external customer Inter-segment sales Total sales		-	RM'000	RM'000 - - -	RM'000 -		

\*\* In view of the change of financial year end from 30 September 2023 to 31 March 2024, there is no comparative figure for the preceding period-to-date.

#### A10. Valuation of property, plant and equipment

The Group did not revalue any of its property, plant and equipment during the current quarter under review.

### A11. Material events during the interim period

There were no material events during the current quarter ended 31 December 2023.

### A12. Material events subsequent to the end of the interim period

There were no material events subsequent to the financial period ended 31 December 2023.

### A13. Changes in composition of the Group

Other than disclosed below, there were no changes in the composition of the Group for the financial period under review:

 As part of the Group's cost-savings efforts, HC Global Limited, CBSA International Sdn Bhd, HS Ligno Sdn Bhd and Hypercove Sdn Bhd have been struck off during the current quarter under review. These wholly-owned subsidiaries have either ceased operation or have not commenced business since their incorparation;

### A14. Capital commitments

Other than disclosed below, there were no material capital commitments at the end of the current quarter under review:-

	As at 31.12.2023 RM'000
Authorised and contracted for:	
Renovation works	7,512
Sublease of land	33,519
Master Services and License Agreement	9,371
	50,402

### A15. Contingent assets or liabilities

There were no material contingent assets or liabilities at the end of the current quarter under review.

### PART B: EXPLANATORY NOTES PURSUANT TO MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD

### **B1.** Review of performance

### **1.1** Financial review for the current quarter and financial period-to-date

	Individual Period				Cumulative Period			
	Quarter	Quarter			Period	Period		
	ended	ended	Varianc	es	ended	ended	Variano	es
	31.12.2023	31.12.2022	Amount	%	31.12.2023	31.12.2022	Amount	%
	RM'000	RM'000	RM'000		RM'000	RM'000	RM'000	
		**				**		
Revenue	4,652	-	N/A	-	18,348	-	N/A	-
Loss before interest, tax								
and share of results of associates	(10,141)	-	N/A	-	(41,475)	-	N/A	-
Loss before interest and tax	(10,204)	-	N/A	-	(41,960)	-	N/A	-
Loss before tax	(10,424)	-	N/A	-	(42,618)	-	N/A	-
Loss after tax	(10,638)	-	N/A	-	(44,190)	-	N/A	-
Loss attributable to owners								
of the Company	(9,050)	-	N/A	-	(40,562)	-	N/A	-

\*\* In view of the change of financial year end from 30 September 2023 to 31 March 2024, there are no comparative figures for the preceding period quarter and preceding period-to-date.

### **B1.** Review of performance (Cont'd)

### 1.1 Financial review for the current quarter and financial period-to-date (Cont'd)

### Revenue

Revenue for the current quarter under review mainly derived from Healthcare segment and Gloves segment.

The Healthcare segment consists of providing laboratory diagnostic services, genomics and biochemistry screening, distribution of other healthcare and pharmaceutical products, digital healthcare platform solutions, and smart healthcare logistic services. This segment has recorded a revenue of RM2.0 million in the current quarter, an increase of RM0.3 million or 17.6% from RM1.7 million in the immediate preceding quarter. The Healthcare segment has contributed a cumulative revenue of RM7.3 million or 39.9% of the total revenue in the financial period-to-date.

The Financial Services segment consists of moneylending business which contributed a revenue of RM1.2 million or 25.8% in the current quarter and RM7.1 million or 38.5% in the financial period-to-date. This segment has extended a total of RM100.0 million of loans to third party corporate loan debtors and individual loan debtors in the ordinary course of its business as a licensed moneylender in the current quarter under review.

### Loss before interest and tax ("LBIT")

The Group recorded a gross loss of RM6.1 million in the current quarter and RM27.7 million in the financial period-to-date mainly due to stiff competition in the Gloves segment resulting in lower revenue couple with fixed and/or rising labour and overhead costs.

In addition, the Group recorded LBIT of RM10.2 million in the current quarter and RM42.0 million in the financial period-to-date mainly due to the reasons stated above as well as weak performance in the Healthcare segment.

### 1.2. Financial review for the current quarter with the immediate preceding quarter

	Current quarter ended 31.12.2023 RM'000	Immediate preceding quarter ended 30.9.2023 RM'000	Variance Amount RM'000	s %
Revenue Loss before interest, tax and	4,652	3,221	1,431	44.4
share of results of associates	(10,141)	(9,231)	910	9.9
Loss before interest and tax	(10,204)	(9,633)	571	5.9
Loss before tax	(10,424)	(10,165)	259	2.5
Loss after tax	(10,638)	(10,363)	275	2.7
Loss attributable to owners				
of the Company	(9,050)	(8,905)	145	1.6

### Revenue

The Group's revenue for the current quarter increased by RM1.4 million as compared to the immediate preceding quarter mainly due to the increase in revenue from Gloves segment from RM0.7 million in the immediate preceding quarter to RM1.5 million in the current quarter, representing an increase of 114.3%, projected a possible sign of recovery in the gloves industry.

### **B1.** Review of performance (Cont'd)

### **1.2.** Financial review for the current quarter with the immediate preceding quarter (Cont'd)

### LBIT

The Group's LBIT for the current quarter increased by RM0.6 million as compared to the immediate preceding quarter mainly due to a loss on struck off of subsidiaries during the current quarter under review.

### **B2.** Group's prospects

The Glove segment persists in facing substantial fixed costs like depreciation, staff costs, rental expenses and others. Additionally, the oversupply of the global glove industry has intensified competition. The Group's focus will be on improving the performance of the Glove segment through cost improvement as well as directing efforts toward securing new potential customers. Despite the expected long-term growth in global glove demand due to increased healthcare standards and hygiene awareness, leading glovemakers in Malaysia have received substantial negative revisions to this year's forecasts.

Concurrently, in the Healthcare segment, the Group is dedicated to amplifying sales for the array of products and services previously outlined. This encompasses a diversified range of general healthcare-related offerings. These include laboratory diagnostic services, genomics and biochemistry screening, distribution of other healthcare and pharmaceutical products, digital healthcare platform solutions, and smart healthcare logistic services.

In view of the headwinds affecting the glove and healthcare sectors, the Group expects the performance for the financial period ending 31 March 2024 to be challenging. To keep abreast of the ever-changing global trends, Hong Seng is constantly exploring initiatives and opportunities to diversify its business activities. The Group will continue to focus on effective cost management, accelerating the transformation into digitalisation and sustainability across its operations to increase productivity and efficiency.

### B3. Statement of the board of directors' opinion on profit estimate, forecast, projection or internal targets

The Group has not provided any profit estimate, forecast, and projection in any public documents.

#### **B4.** Variance on profit forecast

The Group has not issued any profit forecast in any public documents.

#### **B5.** Tax expense

	Individua	l Period	<b>Cumulative Period</b>		
	Quarter ended 31.12.2023 RM'000	Quarter ended 31.12.2022 RM'000	Period-to-date 31.12.2023 RM'000	Period-to-date 31.12.2022 RM'000	
Current tax expense:		**		**	
- For the current financial period	(214)	-	(1,514)	-	
- Underprovision in the					
previous financial period		-	(57)	-	
	(214)	-	(1,571)	-	
Deferred tax expense:					
- For the current financial period	-	-	-	-	
- (Under)/Overprovision in the					
previous financial period		-	-	-	
	-	-	-	-	
	(214)	-	(1,571)	-	

\*\* In view of the change of financial year end from 30 September 2023 to 31 March 2024, there are no comparative figures for the preceding period quarter and preceding period-to-date.

### **B6.** Status of corporate proposal

There were no corporate proposals announced but not completed as at 20 February 2024, being the last practicable date from the date of issue of this report.

### **B7.** Group's borrowings and debts securities

The details of the Group's borrowings and debts securities outstanding are as follows:-

	As at 31.12.2023			As at 30.9.2022			
	Long Term RM'000	Short Term RM'000	Total RM'000	Long Term RM'000	Short Term RM'000	Total RM'000	
Secured							
Lease liabilities Bank borrowings	12,750 10,680	1,322 1,351	14,072 12,031	559 12,319	374 1,291	933 13,610	
Total borrowings	23,430	2,673	26,103	12,878	1,665	14,543	

All borrowings are denominated in Ringgit Malaysia and the Group does not have foreign currency borrowings.

The borrowings bear interest from 2.02% to 5.95% (30.9.2022: 2.02% to 5.95%) per annum.

### **B8.** Material litigation

The Group is not engaged in any material litigation either, as plaintiff or defendant, and the Directors do not have any knowledge of any proceedings pending or threatened against the Group as at the date of this report.

### **B9.** Dividends

No dividend has been declared/paid during the quarter under review.

#### **B10.** Loss per share

#### **10.1** Basic loss per share

The basis loss per share is calculated by dividing the loss after taxation attributable to the ordinary equity holders of the parent by the weighted average number of ordinary shares in issue during the financial period.

		Individual Period		<b>Cumulative Period</b>	
		Quarter ended 31.12.2023	Quarter ended 31.12.2022 **	Period-to-date 31.12.2023	Period-to-date 31.12.2022 **
Loss attributable to owners of	of the				
Company	(RM'000)	(9,050)	-	(40,562)	-
Weighted average number of					
shares in issue	(Unit'000)	5,108,417	-	5,108,417	-
Basic loss per share	(sen)	(0.18)	_	(0.79)	_

### **B10.** Loss per share (Cont'd)

### **10.2** Diluted loss per share

The diluted loss per share is calculated by dividing the loss after taxation attributable to the ordinary equity holders of the parent by the weighted average number of ordinary shares that would have been issued upon the full conversion of the remaining ICPS and full exercise of the remaining Warrant A and Warrant B.

		<b>Individual Period</b>		<b>Cumulative Period</b>	
		Quarter ended 31.12.2023	Quarter ended 31.12.2022	Period-to-date 31.12.2023	Period-to-date 31.12.2022
		51.12.2025	**	51.12.2025	**
Loss attributable to owners of th					
Company	(RM'000)	(9,050)	-	(40,562)	-
Weighted average number of orc					
shares in issue	(Unit'000)	5,108,417	-	5,108,417	-
Effects of dilution * :					
Effect of outstanding ICPS		-	-	-	-
Effect of outstanding warrants			-	-	
Adjusted weighted average num	per of				
ordinary shares in issue	(Unit'000)	5,108,417	-	5,108,417	-
Diluted loss per share	(sen)	(0.18)	_	(0.79)	

Note:-

- \* The effects of potential ordinary shares arising from the conversion of ICPS and exercise of warrants are antidilutive and accordingly, they have been ignored in the calculation of dilutive loss per share. As a result, the dilutive loss per share is the same as basic loss per share.
- \*\* In view of the change of financial year end from 30 September 2023 to 31 March 2024, there are no comparative figures for the preceding period quarter and preceding period-to-date.

### **B11.** Qualification of financial statements

The Company's preceding annual financial statements were not subject to any audit qualifications.

### B12. Notes to statements of profit or loss and other comprehensive income

	Individual Period		<b>Cumulative Period</b>	
	Quarter ended 31.12.2023 RM	Quarter ended 31.12.2022 RM **	Period-to-date 31.12.2023 RM	Period-to-date 31.12.2022 RM **
Bad debts (recovered)/written off	(1)	~~ -	3,063	~~ -
Depreciation on property, plant and equipment	3,208,883	-	14,674,300	-
Forfeited deposit	94,190	-	94,190	-
Impairment loss on receivables	72,653	-	698,370	-
Impairment loss on goodwill		-	2,245	-
(Reversal of) / Inventories written down	(764,269)	-	1,715,987	-
Inventories written off	-	-	172,233	-
Interest expenses	350,108	-	1,559,626	-
Loss on disposal of plant and equipment	-	-	2,905	-
Loss on strike off of subsidiaries	1,226,622	-	1,226,622	-
Loss on unrealised foreign exchange	-	-	96	-
Loss on deemed disposal of an associate	-	-	1,008	-
Plant and equipment written off	-	-	10,774	-
Reversal of impairment loss on receivables	-	-	(27,694)	-
Gain on disposal of plant and equipment	-	-	(18,257)	-
Gain on disposal of a subsidiary	-	-	(483,340)	-
Gain on disposal of an investment	-	-	(5,145,000)	-
Gain on derecognition of lease contract	(479)	-	(1,895)	-
Gain on unrealised foreign exchange	(127)	-	(2,333)	-
Interest income	(130,496)	-	(901,187)	-

\*\* In view of the change of financial year end from 30 September 2023 to 31 March 2024, there are no comparative figures for the preceding period quarter and preceding period-to-date.

### B13. Gains or losses arising from fair value changes of financial liabilities

No gains or losses were recognised for changes in fair values of financial liabilities during the quarter under review.